[1] HUANG C, WANG Y, LI X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet, 2020,395(10223):497-506.
[2] GUAN W J, NI Z Y, HU Y, et al. Clinical characteristics of coronavirus disease 2019 in China[J]. N Engl J Med, 2020,382(18):1708-1720.
[3] CHENG Y, LUO R, WANG K, et al. Kidney disease is associated with in-hospital death of patients with COVID-19[J]. Kidney Int,2020,97(5):829-838.
[4] HUI D, ZUMLA A. Severe acute respiratory syndrome: historical, epidemiologic, and clinical features[J]. Infect Dis Clin North Am, 2019, 33(4):869-889.
[5] RONCO C, REIS T, HUSAIN-SYED F. Management of acute kidney injury in patients with COVID-19[J]. Lancet Respir Med, 2020,8(7):738-742.
[6] YANG X H, SUN R H, CHEN D C. Diagnosis and treatment of COVID-19: acute kidney injury cannot be ignored [J/OL]. Natl Med J China(中华医学杂志), 2020,(3): 242-243-244-245-246 [2020-09-12].
[7] LEE S A, COZZI M, BUSH E L, et al. Distant organ dysfunction in acute kidney injury: a review[J]. Am J Kidney Dis, 2018,72(6):846-856.
[8] Expert Team of Chinese Society of Nephrology. Expert consensus on diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infection with acute kidney injury[J]. Chin J Nephrol(中华肾脏病杂志), 2020, 36(3):242-246.
[9] GRIFFIN B R, FAUBEL S, EDELSTEIN C L. Biomarkers of drug-induced kidney toxicity[J]. Ther Drug Monit, 2019,41(2):213-226.
[10] RONCO C, BELLOMO R, KELLUM J A. Acute kidney injury[J]. Lancet, 2019,394(10212):1949-1964.
[11] SCHISSLER M M, ZAIDI S, KUMAR H, et al. Characteristics and outcomes in community-acquired versus hospital-acquired acute kidney injury[J]. Nephrology (Carlton), 2013,18(3):183-187.
[12] GAO J, TIAN Z, YANG X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies[J]. Biosci Trends, 2020,14(1):72-73.
[13] WANG M, CAO R, ZHANG L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro[J]. Cell Res, 2020,30(3):269-271.
[14] WALKER O, SALAKO L A, ALYÁN G, et al. The disposition of chloroquine in healthy Nigerians after single intravenous and oral doses[J]. Br J Clin Pharmacol, 1987,23(3):295-301.
[15] WANG B, GUO H, LING L, et al. The chronic adverse effect of chloroquine on kidney in rats through an autophagy dependent and independent pathways[J]. Nephron, 2020,144(2):96-108.
[16] MUSABAYANE C T, MUSVIBE A, WENYIKA J, et al. Chloroquine influences renal function in rural Zimbabweans with acute transient fever[J]. Ren Fail,1999,21(2):189-197.
[17] CHOUDHRY V P, MADAN N, SOOD S K, et al. Chloroquine induced haemolysis and acute renal failure in subjects with G-6-PD deficiency[J]. Trop Geogr Med, 1978,30(3):331-335.
[18] CHOUDHRY V P, GHAFARY A, ZAHER M, et al. Drug-induced haemolysis and renal failure in children with glucose-6-phosphate dehydrogenase deficiency in Afghanistan[J]. Ann Trop Paediatr, 1990,10(4):335-338.
[19] RAMOS J W M, SARDINHA J F, COSTA M R, et al. Clinical aspects of hemolysis in patients with P. vivax malaria treated with primaquine, in the Brazilian Amazon[J]. Braz J Infect Dis, 2010,14(4):410-412.
[20] AHMED M H, OSMAN M M. Why does chloroquine impair renal function? Chloroquine may modulate the renal tubular response to vasopressin either directly by inhibiting cyclic AMP generation, or indirectly via nitric oxide[J]. Med Hypotheses, 2007, 68(1):140-143.
[21] KIMURA T, TAKABATAKE Y, TAKAHASHI A, et al. Chloroquine in cancer therapy: a double-edged sword of autophagy [J]. Cancer Res, 2013,73(4):1446.
[22] MÜLLER-HÖCKER J, SCHMID H, WEISS M, et al. Chloroquine-induced phospholipidosis of the kidney mimicking Fabry′s disease: case report and review of the literature[J]. Hum Pathol, 2003,34(3):285-289.
[23] ALBAY D, ADLER S G, PHILIPOSE J, et al. Chloroquine-induced lipidosis mimicking Fabry disease[J]. Mod Pathol, 2005,18(5):733-738.
[24] DEWITTE A, VILLENEUVE J, LEPREUX S, et al. CD154 induces interleukin-6 secretion by kidney tubular epithelial cells under hypoxic conditions: inhibition by chloroquine[J]. Mediators Inflamm, 2020,2020:6357046.
[25] OLDFIELD V, PLOSKER G L. Lopinavir/ritonavir: a review of its use in the management of HIV infection[J]. Drugs, 2006,66(9):1275-1299.
[26] YAO T T, QIAN J D, ZHU W Y, et al. A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-a possible reference for coronavirus disease-19 treatment option [J]. J Med Virol, 2020,92(6):556-563.
[27] MOCROFT A, KIRK O, REISS P, et al. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients[J]. AIDS,2010,24(11):1667,1678.
[28] RYOM L, MOCROFT A, KIRK O, et al. Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study[J]. J Infect Dis, 2013,207(9):1359-1369.
[29] BONJOCH A, PUIG J, PÉREZ-ALVAREZ N, et al. Impact of protease inhibitors on the evolution of urinary markers: subanalyses from an observational cross-sectional study[J]. Medicine (Baltimore), 2016,95(32):e4507.
[30] CHUGHLAY M F, NJUGUNA C, COHEN K, et al. Acute interstitial nephritis caused by lopinavir/ritonavir in a surgeon receiving antiretroviral postexposure prophylaxis[J]. AIDS, 2015,29(4):503-504.
[31] MA P,GONG L,ZHANG N, et al. Analysis of the safety signals of lopinavir/ritonavir based on FDA adverse event database[J]. Chin J Mod Appl Pharm(中国现代应用药学), 2020, 37(4):406-413.
[32] MOCROFT A, LUNDGREN J D, ROSS M, et al. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study[J]. Lancet HIV,2016,3(1):e23-e32.
[33] KALEMEERA F, MBANGO C, MUBITA M, et al. Effect of changing from first- to second-line antiretroviral therapy on renal function: a retrospective study based on data from a single health facility in Namibia [J]. Expert Rev Anti Infect Ther,2016,14(8):777-783.
[34] ZIMMERMANN A E, PIZZOFERRATO T, BEDFORD J, et al. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions[J]. Clin Infect Dis, 2006,42(2):283-290.
[35] CHEN Y W, TANG L Q, ZHANG S Y, et al. Rational administration and pharmaceutical care of interferon alpha nebulization therapy in COVID-19[J]. Chin J Hosp Pharm(中国医院药学杂志), 2020,40(6):632-635.
[36] WU L, XIE W. Adverse effects of interferon-α and coping strategies[J]. Chin J Clin(中国临床医生), 2012, 40(4):18-20.
[37] WU B, XIAO G R, LUO M. Data Mining and Safety Analysis of Drugs for Novel Coronavirus Pneumonia Treatment Based on FAERS: α-interferon[J]. Her Med(医药导报), 2020, 39(4):492-497.
[38] KURSCHEL E, METZ-KURSCHEL U, NIEDERLE N, et al. Investigations on the subclinical and clinical nephrotoxicity of interferon α-2B in patients with myeloproliferative syndromes[J]. Ren Fail, 1991, 13(2-3):87-93.
[39] KANUNGO S, TAMIRISA S, GOPALAKRISHNAN R, et al. Collapsing glomerulopathy as a complication of interferon therapy for hepatitis C infection[J]. Int Urol Nephrol,2010,42(1):219-222.
[40] FISHER M E, ROSSINI M, SIMMONS E, et al. A woman with chronic hepatitis C infection and nephrotic syndrome who developed multiple renal lesions after interferon alfa therapy[J]. Am J Kidney Dis, 2004, 44(3):567-573.
[41] AVERBUCH S D, AUSTIN H A I, SHERWIN S A, et al. Acute interstitial nephritis with the nephrotic syndrome following recombinant leukocyte a interferon therapy for mycosis fungoides[J]. New Engl J Med, 1984, 310(1):32-35.
[42] GORDON A, MENAHEM S, MITCHELL J, et al. Combination pegylated interferon and ribavirin therapy precipitating acute renal failure and exacerbating IgA nephropathy[J]. Nephrol Dial Transplant,2004,19(8):2155.
[43] LECHNER J, MALLOTH N, SEPPI T, et al. IFN- induces barrier destabilization and apoptosis in renal proximal tubular epithelium[J]. AJP Cell Physiol, 2008, 294(1):C153-C160.
[44] SMOLDERS E J, DE KANTER C T, VAN HOEK B, et al. Pharmacokinetics, efficacy, and safety of hepatitis C virus drugs in patients with liver and/or renal impairment[J]. Drug Saf, 2016,39(7):589-611.
[45] SZABOLCS K, JÀNOS P, WEBER G, et al. Ribavirin acts via multiple pathways in inhibition of leukemic cell proliferation[J]. Anticancer Res, 2009, 29(6):1971-1980.
[46] KNORR J P, CHEWAPROUG D, NEELI S, et al. Severe interferon/ribavirin-induced hyperuricemia and urate nephropathy requiring rasburicase and hemodialysis in a liver transplant recipient[J]. Exp Clin Transplant, 2015,13(6):596-599.
[47] LI Y, ZHAO L. Research status on pharmacological actions and in vitro and in vivo effects of arbidol against respiratory viruses[J]. Chin J Clin Pharmacol(中国临床药理学杂志),2019,35(17):1964-1968.
[48] DENG L, LI C, ZENG Q, et al. Arbidol combined with LPV/r versus LPV/r alone against corona virus disease 2019: a retrospective cohort study[J]. J Infect, 2020, 81(1):e1-e5.
[49] CAO Y. Safety and efficacy of Abidor hydrochloride tablets in the treatment of acute respiratory virus infection [J]. Chin J Mod Drug Appl(中国现代药物应用), 2018, 17(12):101-103.
[50] DU X B, LIU S,WEN L F, et al. Open clinical trial of arbidol tablet in the treatment of naturally acquired influenza [J]. J Cardiovasc Pulm Dis(心肺血管病杂志), 2017, 36(7):518-520.
[51] SU X, XIE Z H, SHI Y, et al. A randomized controlled clinical trial of arbidol in patients with acute viral upper respiratory infection[J]. J Clin Inter Med(临床内科杂志), 2005, 22(10): 25-27.
[52] MEHTA P, MCAULEY D F, BROWN M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression[J]. Lancet,2020,395(10229):1033-1034.
[53] SANTORO D, PELLICANÒ V, VISCONTI L, et al. Monoclonal antibodies for renal diseases: current concepts and ongoing treatments[J]. Expert Opin Biol Ther, 2015,15(8):1119-1143.
[54] SCHIFF M H, KREMER J M, JAHREIS A, et al. Integrated safety in tocilizumab clinical trials[J]. Arthritis Res Ther, 2011,13(5):R141.
[55] UGURLU S, HACIOGLU A, ADIBNIA Y, et al. Tocilizumab in the treatment of twelve cases with aa amyloidosis secondary to familial mediterranean fever[J]. Orphanet J Rare Dis, 2017,12(1):105.
[56] EMERY P, RONDON J, PARRINO J, et al. Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis[J]. Rheumatology (Oxford),2019,58(5):849-858.
[57] PIGA M, CHESSA E, IBBA V, et al. Biologics-induced autoimmune renal disorders in chronic inflammatory rheumatic diseases: systematic literature review and analysis of a monocentric cohort[J]. Autoimmun Rev,2014,13(8):873-879.
[58] IBRAHIM Y F, MOUSSA R A, BAYOUMI A M A, et al. Tocilizumab attenuates acute lung and kidney injuries and improves survival in a rat model of sepsis via down-regulation of NF-κB/JNK: a possible role of P-glycoprotein[J]. Inflammopharmacology, 2020,28(1):215-230.
[59] KDIGO A K I . Kidney disease improving global outcomes. AKI work group: clinical practice guideline for acute kidney injury[J]. Kidney Int, 2012, 2(suppl):1-138.